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paper summarizes the proceedings of the symposium and 
provides an outlook for future research needs and pub-
lic health measures. Since food, pharma and health are 
closely interconnected domains, awareness is needed in 
the medical community about the potential relevance of 
drug–nutrition interactions. Experts and stakeholders 
should advocate for the integration of drug–nutrition eval-
uations in the drug development process. Strategies for the 
individual patients should be developed, by installing drug 
review protocols, screening for malnutrition and integrat-
ing this topic into the general medical advice.
Keywords Public health · Drug–nutrient interactions · 
Micronutrient deficiency · Microbiota · Health benefits
Introduction
The University Medical Center Groningen (UMCG, The 
Netherlands) organizes yearly symposia on different, 
actual topics in the overlapping fields of medicine and 
nutrition as part of its Healthy Ageing program. Over 
the past number of years this event evolved to a think-
tank, resulting in several publications, educational- and 
research collaborations [1–3]. The aim of the 2016 meet-
ing that took place on 12 April at the UMCG was to eval-
uate the role and impact of drug–nutrition interactions 
for people using medication, especially the elderly. The 
focus was on current drugs, however, with the ambition to 
also provide input for future drug development by engag-
ing experts from both academy and industry. The overall 
goal of the meeting was to create awareness, to provide an 
overview of this topic and to foster collaborative activi-
ties. Drug–nutrient interactions are often preventable 
or curable, provided that they are recognized in an early 
Abstract The public health relevance of drug–nutri-
tion interactions is currently highly undervalued and 
overlooked. This is particularly the case for elderly per-
sons where multi-morbidity and consequently polyp-
harmacy is very common. Vitamins and other micronu-
trients have central functions in metabolism, and their 
interactions with drugs may result in clinically relevant 
physiological impairments but possibly also in positive 
effects. On 12 April 2016, the University Medical Center 
Groningen (The Netherlands), as part of its Healthy Age-
ing program, organized a workshop on the public health 
relevance of drug–nutrient interactions. In this meeting, 
experts in the field presented results from recent studies 
on interactions between pharmaceuticals and nutrients, 
and discussed the role of nutrition for elderly, focusing on 
those persons receiving pharmaceutical treatment. This 
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stage. Therefore, more insight in this matter will contrib-
ute to an improved health and well-being of patients. This 
paper summarizes the main messages and conclusions of 
the presentations and following discussions and advocates 
to take actions and integrate the topic “drug–nutrition 
interactions” in scientific research programs and in clini-
cal practice.
Clinical assessment of interactions of drugs 
with nutrients: an urgent unmet need
Whereas drug–drug interactions are widely recognized 
as clinically relevant and are included in most phar-
macovigilance systems, nutrient–drug interactions are 
underexplored, and their assessment is not part of the 
clinical routine. Yet, there is ample data supporting 
the presence and relevance of nutrient–drug interac-
tions, indicating that a systematic assessment would be 
necessary.
The poor translation of results from randomized clini-
cal pharmacological trials to real life is one of the major 
challenges in medicine of the twenty-first century, as 
noted in the Lancet series: “Increasing value, reducing 
waste” [4]. Variation in—non-documented—environ-
mental interacting factors, such as nutrients, or adverse 
drug effects on nutrient status, may be among the con-
tributing factors. This becomes an even more urgent issue 
in the era of ageing societies, with a steady increase in 
the number of elderly with multimorbidity and hence 
increasing prevalence of polypharmacy [5] (Table  1). 
Awareness should be created that multimorbidity is 
no longer a confounder but the focus in this age group 
[6]. In general, pharmacotherapy is approached as the 
sum of separate medicinal treatments where multi-level 
interactions are not tested, and as such is poorly suited 
to the needs of the ageing individual. High costs, several 
adverse effects, conflicting guidelines are involved and 
this complexity makes it prone to multiple errors. Exam-
ples of specific interactions have been recently summa-
rized and discussed elsewhere [7].
Drug–nutrition interactions as adverse drug 
reaction
Adverse drug reactions (ADRs)
Medication-related health problems are a public health 
issue of major relevance, especially in elderly people. In 
the Western world, unintended, negative effects of drug 
use would be cause number three of mortality, immediately 
after cardiovascular disease and cancer. In the European 
Union, drug side effects are estimated to be responsible 
for 197,000 deaths per year [8]. The risk of adverse drug 
reactions (ADRs) increases with advancing years [9]. This 
can be explained by age-related changes in pharmacokinet-
ics and pharmacodynamics, the increased vulnerability of 
elderly people, and by the high prevalence of multi-mor-
bidity and consequently polypharmacy in this age group 
[10], as the number of medications used is the most impor-
tant predictor of the risk of ADRs [7, 9] (Fig. 1). Median 
prevalence of adverse events for elderly in ambulatory care 
is reported to be 23% (IQR 19–31%) [11]. Prevalence of 
ADR-related hospital admissions of 75+ years subjects are 
estimated to be 10% (IQR 8–13%), of which 40% could 
have been prevented [12]. These figures may be underes-
timations, as 94% of the potential ADRs are suspected not 
be reported by health care practitioners, according to a sys-
tematic review of drug surveillance data from 12 countries 
[13]. Also in the premarketing phase, risk assessment has 
its limitations: drug development lines may be too short 
for long-term effects to become clinically manifest and the 
number of patients during the application phases is gener-
ally insufficient to adequately detect rare events [14]. More-
over, children, premenopausal women, and, elderly subjects 
are underrepresented in premarketing trials, just as patients 
having more than one disease and/or using more medica-
tions simultaneously.
Drug–nutrition interactions (DNIs)
However, evaluation of drug safety before and after drug 
approval is principally about the consequences of sin-
gle drugs or interactions between drugs. With exception 
of the effects of whole meals and macronutrients on drug 
action, drug–nutrition interactions (DNIs) are not specifi-
cally addressed during the drug development phase [15]. 
Recognition of DNIs is often hampered by limited nutri-
tional knowledge among researchers and professionals in 
the health care field: Nutrition education in EU medical 
schools is between 0.5–3 days, and in the US about 2.5 
day [16–18]. The lack of nutritional expertise is a plausi-
ble contributor to the already substantial underreporting 
of ADRs. Although drug and supplement use is increasing 
[19], and in particular in elderly populations, prevalence 
Table 1  Effects of polypharmacy on nutritional status
Effect on Effect by
Food intake Gastrointestinal discomfort/poor appetite
Gastrointestinal digestion/absorption
Central nervous system depression
Nutrient absorption Gastrointestinal malabsorption
Metabolism and elimina-
tion of nutrients
Organ impairment (liver, kidney)
Loss of nutrients essential to metabolism
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of polypharmacy and malnourishment is high [20], we 
can only speculate about the clinical relevance and pub-
lic health impact of interactions between drugs and nutri-
tional determinants. Theoretically, however, the impact on 
public health might be substantial, considering the clinical 
relevance of minimal adverse drug effects and an adequate 
nutritional status for health and well-being.
Tool to structure DNIs
A helpful tool to address the relatively unexplored domain 
of DNIs is a classification framework for categorizing 
DNIs. A first distinction is made between the effects of 
meals, individual foods, specific nutrients or nutrition sta-
tus on drug action, and vice versa, the effects of drug use 
on determinants of nutrition status [15, 21]:
• Class 1—effect of obesity and malnutrition on drug 
action,
• Class 2—effect of nutrition on drug action,
• Class 3—effect of specific nutrients or dietary supple-
ments on drug action,
• Class 4—effects of drugs on nutrition status,
• Class 5—effects of drugs on nutrient status.
Class 1 DNIs are about the impact of overweight or mal-
nourishment on drug action. A Class 2 DNI is illustrated by 
dietary fat and lapatinib, a protein kinase inhibitor for the 
treatment of metastatic breast cancer. Compared to fasting, 
the bioavailability of this antineoplastic agent increases by 
168% after a low fat meal and by 325% after a high fat meal 
[22]. Bioavailability of abiraterone, a CYP17 inhibitor for 
the treatment of metastatic prostate cancer, even increases 
tenfold after a high fat meal [23]. These Class 2 interac-
tions may ultimately be related to considerable cost sav-
ings in cancer treatment [22], as the drug leaflets of these 
oncology drugs indicate that the medication should be 
taken without any food. Class 3 DNIs initiated by the con-
current use of drugs and supplements may have advantages 
as well as risks [24]. Beneficial are the increased plasma 
levels of chemoresistance-inducing fatty acid 16:4(n-3) 
observed in human volunteers after consumption of fish 
and fish oil [25]. Oppositely, calcium chelating with a tet-
racycline medication in the gastrointestinal tract is a well-
known example of an undesirable Class 3 interaction. The 
Dutch pharmacovigilance Centre Lareb, however, received 
only 55 reports of these adverse food–drug interactions 
over 25  years (1991–2014), which makes it likely that 
Class 3 DNIs are underreported [26]. Class 4 DNIs refer 
to the effects of drugs on nutrition status on macrolevel, 
which are influenced by a diversity of determinants: from 
the ability to see, smell, taste, eat, and drink, until the final 
excretion of urine and feces. Several publications report 
inverse associations of polypharmacy and use of specific 
drug groups with risk of malnourishment [27, 28]. The last 
category, Class 5 DNIs are about the links between drug 
use and nutrient status. In a sub-cohort of 631 geriatric 
outpatients of the Dutch PanDeMics study, for example 
serum 25-hydroxyvitamin D (25(OH)D) was 10  mmol/l 
lower (p = 0.01) in male subjects using ≥10 medications 
compared to males using fewer medications. Severe poly-
pharmacy was present in 21% of the male patients. Also 
Fig. 1  Increased risk of adverse 
drug reactions in older people
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use of oral antidiabetics, vitamin K antagonists, diuretics, 
and ACE inhibitors was found to be significantly associ-
ated with lower vitamin D levels [29]. Depending on the 
cut-off value, prevalence of vitamin D deficiency in this 
cohort was 50% (25(OH)D <50 nmol/l) or 76% (25(OH)D 
<75 nmol/l). Other drugs, clearly affecting circulating vita-
min D are anti-epileptics, anti-oestrogens, anti-virals, glu-
cocorticosteroids and bisphosphonates [30]. By taking the 
pharmacological mechanism and localization of the inter-
action into account, the individual classes can be further 
split up into subclasses [15, 21].
Interaction between oral contraceptives and folate
Neural tube defects (NTDs) are a group of congenital birth 
defects that affect the central nervous system; the most 
common types of NTD are spina bifida and anencephaly. 
Neural tube closure takes place between 24 and 28  days 
after conception, thus NTD’s occur very early in preg-
nancy, even before most women know that they are preg-
nant. Each year, ca. 300,000 babies are born with NTD 
globally, while in Europe ca. 4500 pregnancies are affected. 
Regional prevalence varies considerably due to differences 
in environmental (e.g., dietary) and genetic factors [31]. In 
a study, conducted in Dutch school-aged children whose 
mothers had low folate status during early pregnancy, cog-
nitive development was assessed. Low prenatal folate levels 
were associated with smaller total brain volume, poorer lan-
guage performance, reduction in memory and learning, and 
decrease in visio-spatial domains. These results indicated 
that insufficient folate status in early pregnancy had long-
lasting effects on the offspring’s cognitive development 
[32]. A review article examined whether folate supple-
mentation before and during early pregnancy could reduce 
NTD and other birth defects without causing adverse out-
comes for mothers or babies. Authors concluded that folic 
acid, alone or in combination with other vitamins and min-
erals, prevented NTD and was safe for the mothers and 
newborns [33]. Furthermore, a dose–response study on red 
blood cell (RBC) folate during pregnancy was conducted: 
RBC folate levels of ≥906  nmol/L (=400  ng/mL) were 
identified as providing the greatest protection from NTD, 
however, insufficient data was available to calculate the risk 
reduction for levels ≥1292 nmol/L. It was also shown that 
a doubling of the RBC folate level is achievable with an 
increased folic acid intake of 0.4 mg per day. Importantly, 
it was also estimated that a 48% reduction in the total NTD 
rate was achievable with an increased population intake of 
0.4 mg per day of folic acid [31, 34].
Surveys indicate that only a small proportion of women 
take folic acid supplements during the periconceptual 
period [31], and this is complicated by the issue that folate 
status is generally low in women. Current recommendations 
in the US and Europe propose that all women planning or 
capable of pregnancy should take folic acid supplements at 
doses of 0.4 mg/day, commencing at least one month before 
conception. However, implementation of these recommen-
dations is unsatisfying: Only 24% of women of childbear-
ing potential consume the recommended intake of folic acid 
in the US. After the introduction of public folic acid aware-
ness campaigns in the UK, The Netherlands, and Australia, 
post-campaign rates of folic acid supplement use were 
below 50% of women of childbearing potential. In addition, 
there is evidence that use of oral contraceptives (OC) may 
reduce folate status. A systematic review and meta-analysis 
of the effect of oral contraceptive use on plasma and RBC 
folate concentrations showed that independently of OC use, 
almost all studies reported much lower mean RBC folate 
values than the protective cut-off levels. However, the mean 
difference in RBC folate concentrations between OC-users 
vs. non-users was clinically significant [35]. It is known 
that oral contraceptive use can lead to low serum and tissue 
concentrations of folate, but the mechanism of this effect is 
uncertain. According to some hypotheses, OC may inter-
fere with the absorption of pteroylpolyglutamates or might 
cause malabsorption of dietary folate by inhibition of jeju-
nal folate conjugase, however, this was not confirmed by 
in vitro studies. Oral contraceptive users have normal folate 
absorption but show increased serum clearance and urinary 
excretion of folates. A possible mechanism for increased 
folate excretion would be a change in serum binding pro-
teins for folate. Low serum folate in OC users could also be 
explained by enzyme induction in the liver [36]. Estrogen 
levels of OC were consequently reduced from 150 µg in the 
1960s to 20–50  µg after 1988, while many of the studies 
were conducted in the 1970s and evidence from trials using 
modern OC is very limited. Also, little information is avail-
able on confounders such as dietary folate. Wilson et  al. 
states that insufficient data is available for a definitive con-
clusion regarding the effect of modern OC on folate status 
[37]. However, based on the above it is clearly confirmed 
and evident, that folate status in women of reproductive age 
should be adequate as neural tube closes before pregnancy 
(Fig. 2).
It has been proposed that folate-fortified OC are an 
efficient way to maintain adequate blood folate levels 
for women of reproductive age [31]. In an RCT, women 
received OC with folate or l-5-methyltetrahydrofolate 
(l-5-MTHF) for 24 weeks and OC alone for an additional 
20 weeks (folate elimination phase). An OC fortified with 
folate or l-5-MTHF for 6  months lead to a significant 
increase and maintenance in folate status in women of 
reproductive age [38, 39]. Co-administration of folate with 
OC increased RBC folate levels above ‘NTD-protective’ 
threshold of >906 nmol/L within eight or ten weeks after 
S27Eur J Nutr (2017) 56 (Suppl 2):S23–S36 
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commencement of regular use of l-5-MTHF or folate, 
respectively. The protective levels were maintained for 
10 or 8  weeks after cessation of intake for l-5-MTHF or 
folate, respectively [40]. Thus, folate-fortified OC have the 
potential to protect against NTD, especially considering 
that about half of the pregnancies are unplanned, 21.1% of 
women become pregnant in one menstrual cycle after stop-
ping OC use and 45.7% conceive within three cycles after 
stopping OC use.
Interaction of vitamin D and vitamin K to prevent 
calcification
Despite the availability of lifestyle and pharmacological 
interventions targeting cardiovascular risk factors includ-
ing hypertension, hypercholesterolemia, and diabetes, their 
efficacy to reduce cardiovascular risk is limited. This par-
ticularly applies to high-risk populations such as patients 
with chronic kidney disease [41]. The resulting high resid-
ual cardiovascular risk underscores the need to identify and 
target additional pathways. Vascular calcification contrib-
utes to stiffening of the vasculature, which is a main driver 
of cardiovascular diseases including heart failure with pre-
served ejection fraction (HFpEF). Vascular calcification is 
a complex process directed by the interplay between pro- 
and anti-calcification factors. Vitamin D and K both influ-
ence the process of vascular calcification. Although not a 
classical example of drug–nutrition interactions, the vari-
ous preventive and therapeutic applications of both nutri-
ents qualify the case for further elaboration within the con-
text of this article.
Animal studies suggest that vitamin D plays a key 
role in the prevention of vascular calcification. Vitamin 
D receptor knockout mice display vascular calcification 
[42], and treating animals prone to develop calcifica-
tions with vitamin D provides vascular protection [43]. 
Importantly, exposing animals to excessive amounts of 
vitamin D (receptor activators) may have adverse effects, 
with enhanced vascular calcification [43]. This is a warn-
ing sign also observed in patients; a recent analysis of the 
PREVEND cohort showed that, although an inverse asso-
ciation between 25(OH) vitamin D and the risk of hyper-
tension was observed, the opposite was the case for the 
active metabolite 1.25(OH)2 vitamin D [44]. Each 1-SD 
decrement of 1.25(OH)2 vitamin D was associated with a 
10% lower hypertension risk, independent of potential con-
founders. The same dilemma was observed in the ViRTUE-
CKD trial, which demonstrated that the vitamin D receptor 
activator paricalcitol lowers albuminuria in chronic kid-
ney disease patients, but at the same time increases mark-
ers of deregulated phosphate homeostasis (i.e., fibroblast 
growth factor 23) and vascular calcification propensity 
[45]. Overall, it seems that (25-OH) vitamin D deficiency 
has the most relevant impact on clinical outcomes. A recent 
large meta-analysis showed that in the elderly, vitamin D 
deficiency is associated with a higher risk of cardiovascu-
lar mortality [46]. In the general population, the need for 
vitamin D supplementation to prevent mortality remains 
a matter of debate. In a Cochrane meta-analysis includ-
ing data from 56 RCTs containing overall 95,286 partici-
pants, it was found that cholecalciferol (vitamin D3), but 
not ergocalciferol (vitamin D2), alfacalcidol or calcitriol 
reduced mortality upon long-term (mean 4.4  years) treat-
ment [47]. The authors calculated that 150 people need to 
be treated with vitamin D3 over five years to prevent one 
additional death, which may seem reasonable from a pub-
lic health perspective. In contrast, a recent trial sequential 
meta-analysis suggested a limited effect of vitamin D sup-
plementation on non-skeletal outcomes [48]. However, the 
methodology used in this paper has been heavily criticized 
in the scientific community [49–51].
The vitamin K-dependent matrix-gla protein (MGP) is 
among the most powerful endogenous calcification inhibi-
tors [52]. Several animal studies have shown that vitamin 
K insufficiency contributes to vascular calcification, which 
can be reversed by vitamin K supplementation [53–55]. In 
a state of vitamin K insufficiency, undercarboxylated MGP 
species including desphospho-undercarboxylated MGP 
(dp-ucMGP) are elevated in the circulation. Epidemiologi-
cal studies have consistently shown independent associa-
tions of high circulating dp-ucMGP levels with both arte-
rial stiffness [56] and adverse cardiovascular outcomes 
in high-risk patients including patients with aorta valve 
stenosis [57], cardiovascular disease [58], CKD [59], and 
renal transplant recipients [60]. Currently, ongoing clini-
cal trials addresses the effect of vitamin K supplementation 
on vascular calcification in hemodialysis patients [61] and 
patients with coronary artery disease [62]. Higher vitamin 
K intake reduced dp-ucMGP [63], and has been associated 
with a lower risk of aorta calcification and (cardiovascular 
Fig. 2  Folate status in women of reproductive age should be ade-
quate to prevent neural tube defects (NTDs)
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and all-cause) mortality in the general population. These 
observations suggest that increasing vitamin K intake could 
be a successful strategy to reduce cardiovascular risk [64].
Little is known about the interplay between vitamins D 
and K in relation to vascular calcification. The availability 
of a novel serum calcification propensity assay [65] will 
importantly facilitate studies prospectively addressing cal-
cification risk. A higher calcification propensity has con-
sistently been associated with a higher (cardiovascular) 
mortality risk in patients with CKD [66] and renal trans-
plant recipients [67]. An integrated nutritional intervention, 
including the targeting of vitamin D and K deficiencies, 
may eventually turn out to be the most fruitful approach 
to retard vascular calcification and improve cardiovascular 
prognosis in high-risk patients.
Omega‑3 benefits
Previously, conventional research in nutrition has focused 
on dietary intake of the two marine omega-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA). However, this approach has inherent methodologi-
cal issues: Food Frequency Questionnaires often result in 
implausible data, look up tables are usually outdated and 
issues of bioavailability, like inter-individual variability or 
dependency on matrix effects are ignored [68–71]. It is no 
wonder that there is no agreement of recommendations on 
this basis [72].
It is known that EPA and DHA content of many cells 
is reflected in erythrocytes, therefore, erythrocyte EPA plus 
DHA is used as a biomarker with low biological variability 
for the status of an individual in these two fatty acids. On 
this basis, a standardized analytical procedure, validated 
for 26 fatty acids, with low analytical variability has been 
established: The “HS-Omega-3  Index®” [73]. It is sup-
ported by the largest database of all methods of fatty acid 
analyses, backed up by 212 publications and >50 ongoing 
research projects. The HS-Omega-3 Index is representa-
tive for heart and breast tissues in humans, and in experi-
mental animals it is representative for kidney, cerebral 
cortex, liver, lung and gut tissues; there is almost no cor-
relation with intake [69, 74–77]. A target range for the HS-
Omega-3 Index has been defined as 8–11% EPA plus DHA 
in total erythrocyte fatty acids [78]. Lower levels are asso-
ciated with increasing risk for total mortality and cardio-
vascular events like fatal and non-fatal myocardial infarc-
tion, sudden cardiac death, development of and death from 
congestive heart failure [78]. Determining the HS-Omega-3 
Index in addition to assessing conventional risk factors pro-
vides incremental information, and individuals at medium 
risk for cardiovascular events can be reclassified into the 
high or the low risk category. This can be then the basis 
of a therapeutic consequence. Increasing the HS-Omega-3 
Index caused improvements in surrogate and intermediate 
parameters in pertinent intervention trials (Fig. 3). Accord-
ing to the criteria of the American Heart Association, the 
HS-Omega-3 Index is a novel biomarker for cardiovascular 
risk. Among diseases associated with low omega-3 levels 
are hypertension, congestive heart failure, atrial fibrilla-
tion, coronary artery disease, and peripheral atherosclerosis 
[78].
In contrast, a series of meta-analyses on large interven-
tion trials with EPA and DHA did not find reductions in 
mortality or cardiovascular events. In the pertinent trials, 
EPA and DHA were frequently given as capsules at break-
fast, thus inadvertently minimizing bioavailability. Moreo-
ver, participants were recruited irrespective of baseline 
Fig. 3  Effects of increasing 
the HS-Omega-3 Index on sur-
rogate parameters
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levels of EPA and DHA, and the large inter-individual 
variability in uptake of EPA and DHA was unknown. As 
demonstrated in one large trial, this design leads to over-
lapping levels of EPA and DHA throughout the study [79]. 
Low bioavailability and overlapping levels are thought to 
contribute substantially to neutral outcomes of many large 
trials [78]. This is supported by the fact that trials maximiz-
ing bioavailability using fatty fish as a source for EPA and 
DHA, or trials in patients with low baseline levels (e.g., in 
patients with congestive heart failure) or trials using high 
doses had positive results [80–82]. However, to convince 
cardiologists, a new generation of HS-Omega-3 Index-
based large intervention study in the cardiovascular area is 
probably needed.
A low HS-Omega-3 Index or low levels of EPA and 
DHA in other fatty acid compartments can also be found 
in issues of brain health: Poor brain development (struc-
ture and function), attention-deficit-hyperkinetic disorder 
(ADHD), poor social behavior, emotional lability, major 
depression, suicide or cognitive decline (memory, reaction 
time, executive function) and others [83–85]. Trials using 
higher doses of EPA and DHA (e.g. >750 mg DHA/day) 
usually had positive results in these issues of brain func-
tion, as substantiated by a series of pertinent meta-analyses 
[86]. Of note, brain structure and function was found to be 
improved in healthy individuals.
Furthermore, a low HS-Omega-3 Index or low levels 
of EPA  +  DHA are associated with an increased risk for 
a number of other conditions like stroke [87], osteoporo-
sis [88], rheumatoid arthritis [89], psychopathology and 
aggression [90], or delayed onset muscle soreness [91]. 
Since sources of EPA and DHA disappear from our diet 
and endogenous synthesis is impossible, on a population 
level symptoms of a deficit become more frequent. When 
studied, e.g., by national statistic administrations, >80% of 
the populations had a HS-Omega-3 Index below the target 
range of 8–11% [92]. The dogma that for healthy people, 
eating a normal diet, food supplements are unnecessary is 
wrong in this case [93]. The health of heart, brain and some 
other organs depends on a sufficient status in EPA and 
DHA. The widespread deficit in EPA + DHA can thus be 
conveniently diagnosed and safely treated.
It is well-established, that lipid-lowering therapy with 
statins can significantly reduce the incidence of cardio-
vascular disease and the risk of coronary events. However, 
aggressive lowering of LDL cholesterol by statins comes 
with the risk of lowering polyunsaturated fatty acid (PUFA) 
concentrations as well [94], and mitigating the health ben-
efits of omega-3 fatty acid supplementation [95]. Consid-
ering the widespread use of this drug group and the inad-
equate omega-3 PUFA status of many people worldwide 
[96], it is possible that statin use may be one contributing 
factor to that situation. The residual risk of cardiovascular 
events after treatment with statins might be explained in 
part by the low n-3 PUFA status of patients [97]. Further-
more, a clinically significant additive effect for most cardio-
vascular events was observed for n-3 PUFAs in patients on 
statin treatment [98]. Even though statins are established as 
one of the leading treatment forms to reduce CVD risk, it 
appears that there is an opportunity to further reduce this 
risk by omega-3 PUFA.
Based on mechanistic data, and some case reports, con-
cerns have been raised that high doses of omega-3 fatty 
acids predispose to bleeding events [99, 100]. These con-
cerns, however, could not be substantiated by clinical data:
• in all trials with omega-3 fatty acids in cardiovascular 
patients (with a total of >75,000 participants), most par-
ticipants were using some kind of platelet inhibitor like 
aspirin [78, 101]. Although a safety issue included in 
the study protocols, increased bleeding was not reported 
from the omega-3 groups [78, 101].
• a total of 826 patients on phenprocoumon because of a 
thromboembolic event aged ≥65  years were observed 
for 3  years. Patients in the highest tertile of their 
Omega-3 Index lived longer than patients in the lower 
tertiles, but bleeding events were evenly distributed 
among tertiles [102].
• a total of 1523 patients with an acute myocardial infarc-
tion were treated with platelet inhibitors, anticoagulants 
and a number of other agents, as demanded by cur-
rent guidelines. Bleeding events had no relation to the 
Omega-3 Index of these patients [103].
• intravenous omega-3 fatty acids given before an opera-
tion rather improved outcome, but had no effect on 
bleeding [104, 105].
• the US-American Federal Drug Administration regards 
up to 3  g/day of EPA plus DHA as safe (Docket No. 
91N-0103), while its European counterpart considers up 
to 5  g/day of EPA as safe (http://www.efsa.europa.eu/
en/press/news/120727.htm).
Taken together, although a clinically relevant interac-
tion between drugs affecting platelet function and/or the 
coagulation system and the nutrient omega-3 fatty acids has 
been claimed, systematic data and regulatory authorities do 
not support this claim. Thus, this interaction remains to be 
proven.
Drugs and disturbance of microbiota
It is estimated that in the human body, there are approxi-
mately the same number of bacterial cells as human cells. 
The human gut microbiome is a complex ecosystem that is 
considered to be both an immune and a metabolic organ. 
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Genes, lifestyle, medication, nutrients and their metabo-
lites all influence gut microbiota, however, the effect of 
this interaction on disease development is uncertain. Nev-
ertheless, several bacteria have been associated with many 
diseases [106–109] and fecal transplantation is already an 
emerging method to treat certain conditions.
In the recent years, population cohorts of healthy indi-
viduals have been applied for the analysis of multiple fac-
tors influencing microbiota composition. The LifeLines 
observational follow-up study encompasses in total 165,000 
individuals within a 3-generation design. Data collection 
is complete for multiple questionnaires, different biologi-
cal, and phenotype information. A follow-up questionnaire 
is filled out every year, completed with screening every 
5 years for a total duration of 30 years [110, 111]. The Life-
Lines-DEEP project collects extra “omics” data in a sub-
set of the cohort (n = 1500), e.g., genome-wide polymor-
phisms and different metabolites, and analyses the relation 
between various internal and environmental factors and the 
microbiome. Within this project, it has been shown that due 
to the differences in these factors, microbiome composition 
is highly variable across individuals [112] (Fig. 4).
Further analyses revealed that drugs like proton pump 
inhibitors (PPI), statins and antibiotics considerably affect 
gut microbiome composition. PPIs are widely used to treat 
heartburn symptoms, it is estimated that about 25% of the 
population takes medication from this drug group when 
necessary [113]. According to Dutch data, 7% of the popu-
lation in The Netherlands used omeprazole in 2013 [114]. 
PPI use is especially overrepresented in obese persons, 
elderly people, patients with non-alcoholic fatty liver dis-
ease or non-alcoholic steatohepatitis (NAFLD, NASH), 
irritable bowel syndrome (IBS) and inflammatory bowel 
disease (IBD). A meta-analysis of 300,000 patients showed 
that PPI use was associated with 65% increase in Clostrid-
ium difficile-associated diarrhea, and PPIs increased the 
risk of C. difficile recurrence. According to another meta-
analysis of 11,280 patients, PPIs increased the risk of 
Salmonella, Campylobacter ant other enteric infections 
[115–118]. Furthermore, PPI use is associated with pro-
found alterations in the gut microbiome, namely a lower 
diversity can be observed in PPI users. Since PPIs can have 
negative effect on microbiota composition, it has been pro-
posed that microbiome research in humans should be cor-
rected for PPI use.
A strong correlation of antibiotics has been described 
with several species of the microbiome. Among others, 
antibiotics decrease occurrence of Bifidobacterium longum, 
Bifidobacterium adolescentes, Roseburia inulinivorans 
and increase occurrence of Lachnospiraceae bacterium 
2_1_58FAA and Veillonella parvula. However, in Dutch 
population the effect of antibiotics on the population level 
is less strong, than the effect of PPI: the reason for that is 
low consumption of antibiotics in the Netherlands com-
pared to other countries. Regarding the correlation of sta-
tin use with microbiome composition, research is emerging 
(e.g., Dorea longicatena is negatively associated with statin 
use), with many questions to be answered. This effect can 
partly be explained by the association of microbiome with 
lipid levels that have been identified in several human and 
mouse studies [119].
Currently, what we know is that several drug groups 
can have a strong effect on gut microbiome. As discussed 
above, PPIs are not benign in this respect, since they can 
cause unhealthy changes in the microbiome. Antibiotics 
might have a small effect on population scale, but this can 
be substantial for the individuals. Further research faces 
challenges in dissecting the complex effect of diet, disease, 
and medication.
Clinical assessment of interactions of drugs 
with nutrients: how to approach
As noted before, elderly people are vulnerable in many 
aspects, including nutritional status. This warrants a 
systematic assessment of nutrient–drug interactions, 
starting with classes of drugs that are used in the com-
mon complex disorders that account for the global bur-
den of disease of our time. Today, medicine is clearly 
pharma-dominated where nutrition plays only a con-
founder role. However, especially lifestyle-related dis-
orders would need a better integrated approach of food 
and pharma, even for conditions where lifestyle manage-
ment is already incorporated in clinical guidelines, such 
as hypertension and diabetes. Clinical trials currently 
assess adverse effects only, nutritional background is 
Fig. 4  Explained variance of microbiome composition by different 
factors
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not specified. There is no search for the best nutritional 
background that fits the study purpose, even for condi-
tions where evidence for interaction of nutritional factors 
with pharmacological efficacy, or adverse drug effects, 
was available early in the course of drug development, as 
was the case for interaction of renin–angiotensin–aldos-
terone-blockade and sodium intake [120]. Accordingly, 
investigator brochures focus on toxicity, without assess-
ment of favorable or adverse nutritional conditions that 
blunt or potentiate drug effect. Post-marketing surveil-
lance and guidelines also address adverse effects; nutri-
tional recommendations are alongside but not integrated 
with pharmacological recommendations. Moreover, qual-
ity indicators focus on drug prescription only. Taken 
together, neglect of nutritional factors can result in lack 
of efficacy of pharmacotherapy, even when the latter is 
considered standard of care, based on evidence from ran-
domized clinical trials, and adopted in current guidelines 
[121]. Proper consideration of nutritional status in drug 
action, and assessment of adverse drug effects on nutri-
tional status clearly requires a paradigm change towards 
inclusion of nutritional assessment throughout the stages 
of drug development and evaluation, ranging from early 
stage experimental work, through clinical investiga-
tions, approval and eventually post-marketing surveil-
lance. Spontaneous reporting of adverse drug effects in 
clinical practice should be stimulated, with special atten-
tion for nutrition-related events. Strategies for individ-
ual patients should include development of drug review 
protocols, and assessment and integration of nutritional 
factors and consequences. If possible, clinicians should 
standardly screen for malnutrition, register measurements 
of global nutrition status and of dietary supplements 
used. The proposed framework for categorizing DNIs 
can be of help structuring these consequences. A neces-
sary condition for working with this framework is more 
nutritional knowledge amongst health care practitioners 
and researchers, which might be achieved by integrat-
ing nutritional education in the curricula of schools of 
medicine and pharmacology. Development of a toolbox 
of nutritional readouts would greatly facilitate this pro-
cess. One should start with “usual suspects” as models 
for a systematic approach and use “low hanging fruits” 
(e.g., quantified assessment of diet) for concept develop-
ment and relatively rapid benefit. In addition, 24-h urine 
analysis as a tool for nutritional profiling would allow 
assessments that are more sophisticated. Examples from 
several disciplines (e.g., oncology and nephrology) have 
demonstrated the huge potential gains of proper integra-
tion of nutritional and pharmacological management, 
therefore, engagement of both pharma and food industry 
in food–drug interactions is of paramount importance 
for further development. Finally, communicating the 
outcomes of these recommendations is of crucial interest 
to integrate DNIs in health care.
Conclusions
Since from public health perspective the field of 
drug–nutrition interactions is currently highly underval-
ued and overlooked, this paper addressed various aspects 
of this complex topic. We still observe a continuous pro-
gress in increasing life expectancy, however, during the last 
two decades several considerable changes occurred. One 
example is that in the US, the life expectancy of Cauca-
sians is decreasing, most probably due to lifestyle-related 
factors like increased stress, drugs abuse, lower socioeco-
nomic status, unhealthy diet and increased prevalence of 
obesity, leading to the current diabetes epidemic, NAFLD, 
etc. To reverse this trend and achieve a positive change 
and improvement in public health, multiple conditions are 
simultaneously required, most importantly collaboration 
among all relevant stakeholders and inevitably the govern-
mental will to make improvements happen. Multimorbidity 
among adults is rapidly escalating with age, in the elderly 
it is the common status, not an exception any more. This 
consequently leads to polypharmacy, increasing the risk for 
major drug–drug interactions. Vitamins as essential nutri-
ents have central functions in metabolism, thus interactions 
and insufficient availability of vitamins can result in critical 
impairments of metabolism. Although multiple examples 
of interactions of drugs with micronutrients are reported, 
only a small part has been addressed in this paper. These 
are relatively well-studied cases, but multi-drug interac-
tions have not been tested so far. The question is what can 
be done in this respect to the benefit of the patients. Since 
food–pharma–health are interconnected domains, one of 
the most important actions is to generate higher awareness 
in the medical community of the potential interactions, e.g., 
by integrating this topic into the education plans of medical 
students. On the other hand, nutritional sciences and food 
industry should also develop an open mind towards inter-
action and collaboration with the medical domains. It is of 
paramount importance to further advocate for the integra-
tion of drug–nutrition evaluation processes as an essential 
part of the drug research and development. Strategies for 
the individual patients should also be developed, by install-
ing drug review protocols, screening for malnutrition and 
integrating this topic in the general medical advice.
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